Cymbalta

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
21-12-2021
产品特点 产品特点 (SPC)
21-12-2021
公众评估报告 公众评估报告 (PAR)
18-01-2010

有效成分:

duloxetine

可用日期:

Eli Lilly Nederland B.V.

ATC代码:

N06AX21

INN(国际名称):

duloxetine

治疗组:

Psychoanaleptics,

治疗领域:

Anxiety Disorders; Diabetic Neuropathies; Depressive Disorder, Major

疗效迹象:

Treatment of major depressive disorder.Treatment of diabetic peripheral neuropathic pain.Treatment of generalised anxiety disorder.Cymbalta is indicated in adults.

產品總結:

Revision: 32

授权状态:

Authorised

授权日期:

2004-12-17

资料单张

                                34
B. PACKAGE LEAFLET
35
PACKAGE LEAFLET: INFORMATION FOR THE USER
CYMBALTA
30 MG
HARD GASTRO-RESISTANT CAPSULES
CYMBALTA 60 MG
HARD GASTRO-RESISTANT CAPSULES
Duloxetine (as hydrochloride)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any of the side effects talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Cymbalta is and what it is used for
2.
What you need to know before you take Cymbalta
3.
How to take Cymbalta
4.
Possible side effects
5.
How to store Cymbalta
6.
Contents of the pack and other information
1.
WHAT CYMBALTA IS AND WHAT IT IS USED FOR
Cymbalta contains the active substance duloxetine. Cymbalta increases
the levels of serotonin and
noradrenaline in the nervous system.
Cymbalta is used in adults to treat:
•
depression
•
generalised anxiety disorder (chronic feeling of anxiety or
nervousness)
•
diabetic neuropathic pain (often described as burning, stabbing,
stinging, shooting or aching or
like an electric shock. There may be loss of feeling in the affected
area, or sensations such as
touch, heat, cold or pressure may cause pain)
Cymbalta starts to work in most people with depression or anxiety
within two weeks of starting
treatment, but it may take 2-4 weeks before you feel better. Tell your
doctor if you do not start to feel
better after this time. Your doctor may continue to give you Cymbalta
when you are feeling better to
prevent your depression or anxiety from returning
In people with diabetic neuropathic pain it can take some weeks before
you feel better. Talk to your
doctor if you do not feel better after 2 months.
2.
WHAT YOU NEE
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Cymbalta 30 mg hard gastro-resistant capsules
Cymbalta 60 mg hard gastro-resistant capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Cymbalta 30
mg
Each capsule contains 30 mg of duloxetine (as hydrochloride).
_Excipient(s) with known effect_
Each capsule may contain up to 56 mg sucrose.
Cymbalta 60
mg
Each capsule contains 60 mg of duloxetine (as hydrochloride).
_Excipient(s) with known effect _
Each capsule may contain up to 111 mg sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard gastro-resistant capsule.
Cymbalta 30
mg
Opaque white body, imprinted with ‘30 mg’ and an opaque blue cap,
imprinted with ‘9543’.
Cymbalta 60
mg
Opaque green body, imprinted with ‘60 mg’ and an opaque blue cap,
imprinted with ‘9542’.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive disorder.
Treatment of diabetic peripheral neuropathic pain.
Treatment of generalised anxiety disorder.
Cymbalta is indicated in adults.
For further information see section 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Major depressive disorder_
The starting and recommended maintenance dose is 60 mg once daily with
or without food. Dosages
above 60 mg once daily, up to a maximum dose of 120 mg per day have
been evaluated from a safety
perspective in clinical trials. However, there is no clinical evidence
suggesting that patients not
responding to the initial recommended dose may benefit from dose
up-titrations.
Therapeutic response is usually seen after 2-4 weeks of treatment.
3
After consolidation of the antidepressive response, it is recommended
to continue treatment for several
months, in order to avoid relapse. In patients responding to
duloxetine, and with a history of repeated
episodes of major depression, further long-term treatment at a dose of
60 to 120 mg/day could be
considered.
_Generalised anxiety disorder_
The recommended starting dose in patients with generalise
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 21-12-2021
产品特点 产品特点 保加利亚文 21-12-2021
公众评估报告 公众评估报告 保加利亚文 18-01-2010
资料单张 资料单张 西班牙文 21-12-2021
产品特点 产品特点 西班牙文 21-12-2021
公众评估报告 公众评估报告 西班牙文 18-01-2010
资料单张 资料单张 捷克文 21-12-2021
产品特点 产品特点 捷克文 21-12-2021
公众评估报告 公众评估报告 捷克文 18-01-2010
资料单张 资料单张 丹麦文 21-12-2021
产品特点 产品特点 丹麦文 21-12-2021
公众评估报告 公众评估报告 丹麦文 18-01-2010
资料单张 资料单张 德文 21-12-2021
产品特点 产品特点 德文 21-12-2021
公众评估报告 公众评估报告 德文 18-01-2010
资料单张 资料单张 爱沙尼亚文 21-12-2021
产品特点 产品特点 爱沙尼亚文 21-12-2021
公众评估报告 公众评估报告 爱沙尼亚文 18-01-2010
资料单张 资料单张 希腊文 21-12-2021
产品特点 产品特点 希腊文 21-12-2021
公众评估报告 公众评估报告 希腊文 18-01-2010
资料单张 资料单张 法文 21-12-2021
产品特点 产品特点 法文 21-12-2021
公众评估报告 公众评估报告 法文 18-01-2010
资料单张 资料单张 意大利文 21-12-2021
产品特点 产品特点 意大利文 21-12-2021
公众评估报告 公众评估报告 意大利文 18-01-2010
资料单张 资料单张 拉脱维亚文 21-12-2021
产品特点 产品特点 拉脱维亚文 21-12-2021
公众评估报告 公众评估报告 拉脱维亚文 18-01-2010
资料单张 资料单张 立陶宛文 21-12-2021
产品特点 产品特点 立陶宛文 21-12-2021
公众评估报告 公众评估报告 立陶宛文 18-01-2010
资料单张 资料单张 匈牙利文 21-12-2021
产品特点 产品特点 匈牙利文 21-12-2021
公众评估报告 公众评估报告 匈牙利文 18-01-2010
资料单张 资料单张 马耳他文 21-12-2021
产品特点 产品特点 马耳他文 21-12-2021
公众评估报告 公众评估报告 马耳他文 18-01-2010
资料单张 资料单张 荷兰文 21-12-2021
产品特点 产品特点 荷兰文 21-12-2021
公众评估报告 公众评估报告 荷兰文 18-01-2010
资料单张 资料单张 波兰文 21-12-2021
产品特点 产品特点 波兰文 21-12-2021
公众评估报告 公众评估报告 波兰文 18-01-2010
资料单张 资料单张 葡萄牙文 21-12-2021
产品特点 产品特点 葡萄牙文 21-12-2021
公众评估报告 公众评估报告 葡萄牙文 18-01-2010
资料单张 资料单张 罗马尼亚文 21-12-2021
产品特点 产品特点 罗马尼亚文 21-12-2021
公众评估报告 公众评估报告 罗马尼亚文 18-01-2010
资料单张 资料单张 斯洛伐克文 21-12-2021
产品特点 产品特点 斯洛伐克文 21-12-2021
公众评估报告 公众评估报告 斯洛伐克文 18-01-2010
资料单张 资料单张 斯洛文尼亚文 21-12-2021
产品特点 产品特点 斯洛文尼亚文 21-12-2021
公众评估报告 公众评估报告 斯洛文尼亚文 18-01-2010
资料单张 资料单张 芬兰文 21-12-2021
产品特点 产品特点 芬兰文 21-12-2021
公众评估报告 公众评估报告 芬兰文 18-01-2010
资料单张 资料单张 瑞典文 21-12-2021
产品特点 产品特点 瑞典文 21-12-2021
公众评估报告 公众评估报告 瑞典文 18-01-2010
资料单张 资料单张 挪威文 21-12-2021
产品特点 产品特点 挪威文 21-12-2021
资料单张 资料单张 冰岛文 21-12-2021
产品特点 产品特点 冰岛文 21-12-2021
资料单张 资料单张 克罗地亚文 21-12-2021
产品特点 产品特点 克罗地亚文 21-12-2021

搜索与此产品相关的警报

查看文件历史